Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score
- PMID: 21663982
- DOI: 10.1016/j.ijcard.2011.05.071
Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score
Abstract
Background: Identification of patients at risk for major adverse cardiovascular events (MACE) might help selecting candidates for aggressive treatment or early discharge after primary percutaneous coronary intervention (pPCI).
Methods: The RISK-PCI is an observational trial of 2096 consecutive patients who underwent pPCI between 2006 and 2009, randomly allocated to derivation and validation sets with a set ratio of 80% to 20%. Thirty-day MACE comprising death, nonfatal reinfarction and stroke was the primary end point. Multivariable logistic regression was used to determine the independent predictors of outcome. A sum of weighted points for specific predictors was calculated to define the final score.
Results: The RISK-PCI score comprised 12 independent predictors of 30-day MACE, with a graded 125-fold increase in the primary end point with increasing risk score from ≤ 1 to ≥ 15. The model showed good discrimination and calibration for the prediction of 30-day MACE (c-statistic 0.83, goodness-of-fit p = 0.72) and 30-day death (c-statistic 0.87, goodness-of-fit p = 0.56). Bootstrapping with 1000 resample confirmed the stability of the model's performance. Patients were classified into risk classes, with the observed incidence of 30-day MACE of 1.9, 5.9, 13.3 and 39.4% in the low, intermediate, high and very high-risk classes, respectively. An 18-fold graded increase in the primary end point was observed between patients in a low risk class and those in a very high risk class.
Conclusion: We derived a novel risk model to predict 30-day MACE after pPCI, which might help clinician decide the most appropriate treatment in accordance with the patient's risk profile.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Comparison of the predictive value of EuroSCORE, SYNTAX score, and clinical SYNTAX score for outcomes of patients undergoing percutaneous coronary intervention for unprotected left main coronary artery disease.Catheter Cardiovasc Interv. 2012 Aug 1;80(2):222-30. doi: 10.1002/ccd.23450. Epub 2012 Feb 14. Catheter Cardiovasc Interv. 2012. PMID: 22334399
-
Using the RISK-PCI Score in the Long-Term Prediction of Major Adverse Cardiovascular Events and Mortality after Primary Percutaneous Coronary Intervention.J Interv Cardiol. 2019 Oct 24;2019:2679791. doi: 10.1155/2019/2679791. eCollection 2019. J Interv Cardiol. 2019. PMID: 31772519 Free PMC article.
-
Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: rationale and design of the RISK-PCI study.J Interv Cardiol. 2009 Aug;22(4):320-8. doi: 10.1111/j.1540-8183.2009.00476.x. Epub 2009 Jun 8. J Interv Cardiol. 2009. PMID: 19515084
-
Simple risk algorithm to predict serious bleeding in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: RISK-PCI bleeding score.Circ J. 2013;77(7):1719-27. doi: 10.1253/circj.cj-12-1177. Epub 2013 Apr 20. Circ J. 2013. PMID: 23603843 Clinical Trial.
-
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial.Heart Vessels. 2013 Jul;28(4):424-33. doi: 10.1007/s00380-012-0276-z. Epub 2012 Sep 14. Heart Vessels. 2013. PMID: 22975713
Cited by
-
Prediction models for major adverse cardiovascular events after percutaneous coronary intervention: a systematic review.Front Cardiovasc Med. 2024 Jan 8;10:1287434. doi: 10.3389/fcvm.2023.1287434. eCollection 2023. Front Cardiovasc Med. 2024. PMID: 38259313 Free PMC article. Review.
-
T and Small Protrusion (TAP) Technique in Bifurcations: Coronary Artery Disease in Acute Myocardial Infarction Patients after COVID-19 Pneumonia.Biomedicines. 2023 Aug 11;11(8):2255. doi: 10.3390/biomedicines11082255. Biomedicines. 2023. PMID: 37626751 Free PMC article.
-
Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis.J Interv Cardiol. 2023 May 18;2023:4100197. doi: 10.1155/2023/4100197. eCollection 2023. J Interv Cardiol. 2023. PMID: 37251365 Free PMC article. Review.
-
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention.Front Cardiovasc Med. 2023 Feb 8;9:1027892. doi: 10.3389/fcvm.2022.1027892. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36843628 Free PMC article.
-
Application of Modern Clinical Risk Scores in the Global Assessment of Risks Related to the Diagnosis and Treatment of Acute Coronary Syndromes in Everyday Medical Practice.Int J Environ Res Public Health. 2021 Aug 28;18(17):9103. doi: 10.3390/ijerph18179103. Int J Environ Res Public Health. 2021. PMID: 34501692 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
